^
    Back
    Association details:
    Biomarker:FGF19 positive
    Cancer:Hepatocellular Cancer
    Drug:Balversa (erdafitinib) (pan-FGFR inhib)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    PNAS
    Title:

    FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma

    Published date:
    09/30/2022
    Excerpt:
    ...the pan-FGFR inhibitor erdafitinib displayed superior potency than FGFR4-selective inhibitors in suppressing the growth and survival of FGF19-positive HCC cells.
    DOI:
    https://doi.org/10.1073/pnas.2208844119